FINWIRES · TerminalLIVE
FINWIRES

Antengene Secures China IND Approval for Autoimmune Disease Drug

By

Antengene (HKG:6996) said China's National Medical Products Administration has approved an Investigational New Drug (IND) application for a Phase I study of ATG-201, according to a voluntary filing on the Hong Kong Stock Exchange on Wednesday.

The ATG-201 is a CD19/CD3 bispecific T-cell engager antibody targeting B-cell-related autoimmune diseases.

The company plans to promptly initiate the Phase I trial in China while concurrently preparing for clinical development in Australia.

Antengene has secured 33 IND approvals in the U.S. and Asia, 10 NDA approvals across Asia-Pacific markets, and its lead asset XPOVIO (selinexor) is approved in 10 markets and included in five national insurance schemes.

The Group cautions that it cannot guarantee ATG-201 will be successfully developed and marketed.

Related Articles

Asia

Cosmo Chemical Shares Rise 6% on KRW15.5 Billion EcoPro Supply Deal

Cosmo Chemical (KRX:005420) secured a supply contract for cobalt sulfate, a secondary battery cathode material, from EcoPro (KOSDAQ:086520) subsidiary EcoPro EM, according to a Tuesday Korea Exchange filing.The contract, worth 15.47 billion won, is valid till Dec. 31, 2031.Shares of Cosmo Chemical rose nearly 6% in recent trade.

$KOSDAQ:086520$KRX:005420
Asia

Grasim Industries Earmarks INR31 Billion Capex for Lyocell Capacity Expansion

Grasim Industries (NSE:GRASIM, BOM:500300) has received board approval for Phase II expansion of its Lyocell capacity in Harihar, Karnataka, involving capital expenditure of 30.9 billion Indian rupees, according to a Monday filing with the Indian bourses.The expansion will be executed in two phases, adding a total capacity of 110,000 tonnes per annum (TPA) through two 55,000 TPA lines. The first phase is expected to be completed by mid-2028, followed by the second phase by mid-2030.The Phase II expansion will complement Phase I of its Lyocell plant in Harihar, which is already under construction and is expected to be commissioned by mid-2027, the filing stated.

$BOM:500300$NSE:GRASIM
Asia

SEC Wins KRW4.2 Billion Equipment Supply Order from Hanwha Aerospace

South Korean tech and inspection company SEC (KOSDAQ:081180) won an order from Hanwha Aerospace (KRX:012450) to supply the latter with non-destructive testing equipment, according to a Tuesday filing with the Korea Exchange.The contract, worth 4.2 billion won, is valid till Dec. 31, 2027.Shares of Hanwha Aerospace rose nearly 1% in recent trade.

$KOSDAQ:081180$KRX:012450